Heparan sulfate proteoglycans in glomerular inflammation

Kidney International

Volumn 65, Issue 3, 2004, Pages 768-785

  Rops, Angelique L W M M ^b   Van Der Vlag, Johan ^b   Lensen, Joost F M ^b   Wijnhoven, Tessa J M ^b   Van Den Heuvel, Lambert P W J ^b   Van Kuppevelt, Toin H ^b   Berden, Jo H M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Glomerulus; Heparan sulfate proteoglycans; Inflammation; Renal

Indexed keywords

AGRIN; CELL ADHESION MOLECULE; CELL SURFACE PROTEIN; COLLAGEN TYPE 18; GLYCAN; GLYPICAN; HERMES ANTIGEN; L SELECTIN; PERLECAN; PROTEOHEPARAN SULFATE; SYNDECAN;

CELL ACTIVATION; CELL SURFACE; CELLULAR DISTRIBUTION; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GLOMERULITIS; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION; HUMAN; LEUKOCYTE MIGRATION; LEUKOCYTE ROLLING; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; STATISTICAL SIGNIFICANCE; TISSUE DISTRIBUTION; TISSUE INJURY; TREATMENT INDICATION;

EID: 1342343896     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00451.x     Document Type: Article

References (180)

1. CAREY DJ: Syndecans: Multifunctional cell-surface co-receptors. Biochem J 327:1-16, 1997
2. BERNFIELD M, GOTTE M, PARK PW, et al: Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68:729-777, 1999
3. RAATS CJ, VAN DEN BORN J, BERDEN JH: Glomerular heparan sulfate alterations: Mechanisms and relevance for proteinuria. Kidney Int 57:385-400, 2000
4. IOZZO RV: Matrix proteoglycans: From molecular design to cellular function. Annu Rev Biochem 67:609-652, 1998
5. JACKSON RL, BUSCH SJ, CARDIN AD: Glycosaminoglycans: Molecular properties, protein interactions, and role in physiological processes. Physiol Rev 71:481-539, 1991
6. LINDAHL U, KUSCHE-GULLBERG M, KJELLEN L: Regulated diversity of heparan sulfate. J Biol Chem 273:24979-24982, 1998
7. GALLAGHER JT: Structure-activity relationship of heparan sulphate. Biochem Soc Trans 25:1206-1209, 1997
8. ESKO JD, SELLECK SB: Order out of chaos: Assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem 71:435-471, 2002
9. DAVID G: Integral membrane heparan sulfate proteoglycans. Faseb J 7:1023-1030, 1993
10. GOTTE M: Syndecans in inflammation. Faseb J 17:575-591, 2003
11. LEVER R, PAGE CP: Novel drug development opportunities for heparin. Nat Rev Drug Discov 1:140-148, 2002
12. CAPILA I, LINHARDT RJ: Heparin-protein interactions. Angew Chem Int Ed Engl 41:390-412, 2002
13. NETELENBOS T: Role of Proteoglycans on Bone Marrow Endothelium in Stem Cell Homing (chapter 1) (Ph.D. thesis ISBN: 90-9016078-7), Free University Amsterdam, 2002, pp 9-46
14. HAJMOHAMMADI S, ENJYOJI K, PRINCIVALLE M, et al: Normal levels of anticoagulant heparan sulfate are not essential for normal hemostasis. J Clin Invest 111:989-999, 2003
15. ALI S, PALMER AC, BANERJEE B, et al: Examination of the function of RANTES, MIP-1alpha, and MIP-1beta following interaction with heparin-like glycosaminoglycans. J Biol Chem 275:11721-11727, 2000
16. ALI S, PALMER AC, FRITCHLEY SJ, et al: Multimerization of monocyte chemoattractant protein-1 is not required for glycosaminoglycan-dependent transendothelial chemotaxis. Biochem J 358:737-745, 2001
17. AMARA A, LORTHIOIR O, VALENZUELA A, et al: Stromal cell-derived factor-1alpha associates with heparan sulfates through the first beta-strand of the chemokine. J Biol Chem 274:23916-23925, 1999
18. COCKWELL P, CHAKRAVORTY SJ, GIRDLESTONE J, et al: Fractalkine expression in human renal inflammation. J Pathol 196:85-90, 2002
19. DIAMOND MS, ALON R, PARKOS CA, et al: Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD1). J Cell Biol 130:1473-1482, 1995
20. KOENIG A, NORGARD-SUMNICHT K, LINHARDT R, et al: Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 101:877-889, 1998
21. LEE TD, GONZALEZ ML, KUMAR P, et al: CAP37, a novel inflammatory mediator: Its expression in endothelial cells and localization to atherosclerotic lesions. Am J Pathol 160:841-848, 2002
22. LUSTER AD, GREENBERG SM, LEDER P: The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med 182:219-231, 1995
23. MIKHAILOV D, YOUNG HC, LINHARDT RJ, et al: Heparin dodecasaccharide binding to platelet factor-4 and growth-related protein-alpha. Induction of a partially folded state and implications for heparin-induced thrombocytopenia. J Biol Chem 274:25317-25329, 1999
24. NELSON RM, CECCONI O, ROBERTS WG, et al: Heparin oligosaccharides bind L-and P-selectin and inhibit acute inflammation. Blood 82:3253-3258, 1993
25. NORGARD-SUMNICHT K, VARKI A: Endothelial heparan sulfate proteoglycans that bind to L-selectin have glucosamine residues with unsubstituted amino groups. J Biol Chem 270:12012-12024, 1995
26. PARISH CR, FREEMAN C, HULETT MD: Heparanase: A key enzyme involved in cell invasion. Biochim Biophys Acta 1471:M99-M108, 2001
27. SPILLMANN D, WITT D, LINDAHL U: Defining the interleukin-8-binding domain of heparan sulfate. J Biol Chem 273:15487-15493, 1998
28. RAATS CJ, BAKKER MA, VAN DEN BORN J, et al: Hydroxyl radicals depolymerize glomerular heparan sulfate in vitro and in experimental nephrotic syndrome. J Biol Chem 272:26734-26741, 1997
29. RAATS CJ, LUCA ME, BAKKER MA, et al: Reduction in glomerular heparan sulfate correlates with complement deposition and albuminuria in active Heymann nephritis. J Am Soc Nephrol 10:1689-1699, 1999
30. VAN DEN BORN J, VAN KRAATS AA, BAKKER MA, et al: Selective proteinuria in diabetic nephropathy in the rat is associated with a relative decrease in glomerular basement membrane heparan sulphate. Diabetologia 38:161-172, 1995
31. VAN DEN BORN J, VAN DEN HEUVEL LP, BAKKER MA, et al: A monoclonal antibody against GBM heparan sulfate induces an acute selective proteinuria in rats. Kidney Int 41:115-123, 1992
32. VAN DEN BORN J, VAN DEN HEUVEL LP, BAKKER MA, et al: Distribution of GBM heparan sulfate proteoglycan core protein and side chains in human glomerular diseases. Kidney Int 43:454-463, 1993
33. BULLOCK SL, FLETCHER JM, BEDDINGTON RS, et al: Renal agenesis in mice homozygous for a gene trap mutation in the gene encoding heparan sulfate 2-sulfotransferase. Genes Dev 12:1894-1906, 1998
34. TANGELDER GJ, ARFORS KE: Inhibition of leukocyte rolling in venules by protamine and sulfated polysaccharides. Blood 77:1565-1571, 1991
35. WAN JG, MU JS, ZHU HS, et al: N-desulfated non-anticoagulant heparin inhibits leukocyte adhesion and transmigration in vitro and attenuates acute peritonitis and ischemia and reperfusion injury in vivo. Inflamm Res 51:435-443, 2002
36. VAN BRUGGEN MC, WALGREEN B, RIJKE TP, et al: Heparin and heparinoids prevent the binding of immune complexes containing nucleosomal antigens to the GBM and delay nephritis in MRL/lpr mice. Kidney Int 50:1555-1564, 1996
37. XIE X, RIVIER AS, ZAKRZEWICZ A, et al: Inhibition of selectin-mediated cell adhesion and prevention of acute inflammation by nonanticoagulant sulfated saccharides. Studies with carboxyl-reduced and sulfated heparin and with trestatin a sulfate. J Biol Chem 275:34818-34825, 2000
38. WAN MX, ZHANG XW, TORKVIST L, et al: Low molecular weight heparin inhibits tumor necrosis factor alpha-induced leukocyte rolling. Inflamm Res 50:581-584, 2001
39. MANDUTEANU I, VOINEA M, CAPRARU M, et al: A novel attribute of enoxaparin: inhibition of monocyte adhesion to endothelial cells by a mechanism involving cell adhesion molecules. Pharmacology 65:32-37, 2002
40. ADAMS DH, SHAW S: Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet 343:831-836, 1994
41. BUTCHER EC: Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 67:1033-1036, 1991
42. CARLOS TM, HARLAN JM: Leukocyte-endothelial adhesion molecules. Blood 84:2068-2101, 1994
43. GIUFFRE L, CORDEY AS, MONAI N, et al: Monocyte adhesion to activated aortic endothelium: Role of L-selectin and heparan sulfate proteoglycans. J Cell Biol 136:945-956, 1997
44. MAMDOUH Z, CHEN X, PIERINI LM, et al: Targeted recycling of PECAM from endothelial surface-connected compartments during diapedesis. Nature 421:748-753, 2003
45. BAME KJ: Heparanases: Endoglycosidases that degrade heparan sulfate proteoglycans. Glycobiology 11:91R-98R, 2001
46. GOLDSHMIDT O, ZCHARIA E, COHEN M, et al: Heparanase mediates cell adhesion independent of its enzymatic activity. Faseb J 17:1015-1025, 2003
47. VLODAVSKY I, ELDOR A, HAIMOVITZ-FRIEDMAN A, et al: Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis 12:112-127, 1992
48. KANWAR YS, LINKER A, FARQUHAR MG: Increased permeability of the glomerular basement membrane to ferritin after removal of glycosaminoglycans (heparan sulfate) by enzyme digestion. J Cell Biol 86:688-693, 1980
49. GROFFEN AJ, RUEGG MA, DIJKMAN H, et al: Agrin is a major heparan sulfate proteoglycan in the human glomerular basement membrane. J Histochem Cytochem 46:19-27, 1998
50. RAATS CJ, BAKKER MA, HOCH W, et al: Differential expression of agrin in renal basement membranes as revealed by domain-specific antibodies. J Biol Chem 273:17832-17838, 1998
51. NOONAN DM, HASSELL JR: Perlecan, the large low-density proteoglycan of basement membranes: Structure and variant forms. Kidney Int 43:53-60, 1993
52. HALFTER W, DONG S, SCHURER B, et al: Collagen XVIII is a basement membrane heparan sulfate proteoglycan. J Biol Chem 273:25404-25412, 1998
53. EICKELBERG O, CENTRELLA M, REISS M, et al: Betaglycan inhibits TGF-beta signaling by preventing type I-type II receptor complex formation. Glycosaminoglycan modifications alter betaglycan function. J Biol Chem 277:823-829, 2002
54. FILMUS J, SELLECK SB: Glypicans: proteoglycans with a surprise. J Clin Invest 108:497-501, 2001
55. LITWACK ED, IVINS JK, KUMBASAR A, et al: Expression of the heparan sulfate proteoglycan glypican-1 in the developing rodent. Dev Dyn 211:72-87, 1998
56. YAMAMOTO T, WATANABE T, IKEGAYA N, et al: Expression of types I, II, and III TGF-beta receptors in human glomerulonephritis. J Am Soc Nephrol 9:2253-2261, 1998
57. WONG SH, HAMEL L, CHEVALIER S, et al: Endoglin expression on human microvascular endothelial cells association with betaglycan and formation of higher order complexes with TGF-beta signalling receptors. Eur J Biochem 267:5550-5560, 2000
58. TAKAZOE K, TESCH GH, HILL PA, et al: CD44-mediated neutrophil apoptosis in the rat. Kidney Int 58:1920-1930, 2000
59. ROY-CHAUDHURY P, KHONG TF, WILLIAMS JH, et al: CD44 in glomerulonephritis: expression in human renal biopsies, the Thy 1.1 model, and by cultured mesangial cells. Kidney Int 50:272-281, 1996
60. KALLUNKI P, TRYGGVASON K: Human basement membrane heparan sulfate proteoglycan core protein: A 467-kD protein containing multiple domains resembling elements of the low density lipoprotein receptor, laminin, neural cell adhesion molecules, and epidermal growth factor. J Cell Biol 116:559-571, 1992
61. FRIEDRICH MV, GOHRING W, MORGELIN M, et al: Structural basis of glycosaminoglycan modification and of heterotypic interactions of perlecan domain V. J Mol Biol 294:259-270, 1999
62. GREGORY JD, COSTER L, DAMLE SP: Proteoglycans of rabbit corneal stroma. Isolation and partial characterization. J Biol Chem 257:6965-6970, 1982
63. COUCHMAN JR, LJUBIMOV AV, STHANAM M, et al: Antibody mapping and tissue localization of globular and cysteine-rich regions of perlecan domain III. J Histochem Cytochem 43:955-963, 1995
64. BATTAGLIA C, MAYER U, AUMAILLEY M, et al: Basement-membrane heparan sulfate proteoglycan binds to laminin by its heparan sulfate chains and to nidogen by sites in the protein core. Eur J Biochem 208:359-366, 1992
65. BROWN JC, SASAKI T, GOHRING W, et al: The C-terminal domain V of perlecan promotes beta1 integrin-mediated cell adhesion, binds heparin, nidogen and fibulin-2 and can be modified by glycosaminoglycans. Eur J Biochem 250:39-46, 1997
66. HEREMANS A, DE COCK B, CASSIMAN JJ, et al: The core protein of the matrix-associated heparan sulfate proteoglycan binds to fibronectin. J Biol Chem 265:8716-8724, 1990
67. HENRY MD, SATZ JS, BRAKEBUSCH C, et al: Distinct roles for dystroglycan, beta1 integrin and perlecan in cell surface laminin organization. J Cell Sci 114:1137-1144, 2001
68. MONGIAT M, SWEENEY SM, SAN ANTONIO JD, et al: Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J Biol Chem 278:4238-4249, 2003
69. ROSSI M, MORITA H, SORMUNEN R, et al: Heparan sulfate chains of perlecan are indispensable in the lens capsule but not in the kidney. Embo J 22:236-245, 2003
70. GROFFEN AJ, BUSKENS CA, VAN KUPPEVELT TH, et al: Primary structure and high expression of human agrin in basement membranes of adult lung and kidney. Eur J Biochem 254:123-128, 1998
71. RUPP F, PAYAN DG, MAGILL-SOLC C, et al: Structure and expression of a rat agrin. Neuron 6:811-823, 1991
72. TSEN G, NAPIER A, HALFTER W, et al: Identification of a novel alternatively spliced agrin mRNA that is preferentially expressed in non-neuronal cells. J Biol Chem 270:15934-15937, 1995
73. O'TOOLE JJ, DEYST KA, BOWE MA, et al: Alternative splicing of agrin regulates its binding to heparin alpha-dystroglycan, and the cell surface. Proc Natl Acad Sci USA 93:7369-7374, 1996
74. BURGESS RW, SKARNES WC, SANES JR: Agrin isoforms with distinct amino termini: differential expression, localization, and function. J Cell Biol 151:41-52, 2000
75. COLE GJ, HALFTER W: Agrin: An extracellular matrix heparan sulfate proteoglycan involved in cell interactions and synaptogenesis. Perspect Dev Neurobiol 3:359-371, 1996
76. RAATS CJ, VAN DEN BORN J, BAKKER MA, et al: Expression of agrin, dystroglycan, and utrophin in normal renal tissue and in experimental glomerulopathies. Am J Pathol 156:1749-1765, 2000
77. STERK LM, DE MELKER AA, KRAMER D, et al: Glomerular extracellular matrix components and integrins. Cell Adhes Commun 5:177-192, 1998
78. DONG S, COLE GJ, HALFTER W: Expression of collagen XVIII and localization of its glycosaminoglycan attachment sites. J Biol Chem 278:1700-1707, 2003
79. SAARELA J, YLIKARPPA R, REHN M, et al: Complete primary structure of two variant forms of human type XVIII collagen and tissue-specific differences in the expression of the corresponding transcripts. Matrix Biol 16:319-328, 1998
80. O'REILLY MS, BOEHM T, SHING Y, et al: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285, 1997
81. DHANABAL M, RAMCHANDRAN R, WATERMAN MJ, et al: Endostatin induces endothelial cell apoptosis. J Biol Chem 274:11721-11726, 1999
82. MIOSGE N, SIMNIOK T, SPRYSCH P, et al: The collagen type XVIII endostatin domain is co-localized with perlecan in basement membranes in vivo. J Histochem Cytochem 51:285-296, 2003
83. KREUGER J, MATSUMOTO T, VAN WILDEMEERSCH M, et al: Role of heparan sulfate domain organization in endostatin inhibition of endothelial cell function. Embo J 21:6303-6311, 2002
84. BERNFIELD M, KOKENYESI R, KATO M, et al: Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol 8:365-393, 1992
85. RAPRAEGER A, JALKANEN M, ENDO E, et al: The cell surface proteoglycan from mouse mammary epithelial cells bears chondroitin sulfate and heparan sulfate glycosaminoglycans. J Biol Chem 260:11046-11052, 1985
86. SHWORAK NW, SHIRAKAWA M, MULLIGAN RC, et al: Characterization of ryudocan glycosaminoglycan acceptor sites. J Biol Chem 269:21204-21214, 1994
87. COUCHMAN JR, VOGT S, LIM ST, et al: Regulation of inositol phospholipid binding and signaling through syndecan-4. J Biol Chem 277:49296-49303, 2002
88. LIM ST, LONGLEY RL, COUCHMAN JR, et al: Direct binding of syndecan-4 cytoplasmic domain to the catalytic domain of protein kinase C alpha (PKC alpha) increases focal adhesion localization of PKC alpha. J Biol Chem 278:13795-13802, 2003
89. ROSENBERG RD, SHWORAK NW, LIU J, et al: Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated? J Clin Invest 99:2062-2070, 1997
90. COOK DM, HINKES MT, BERNFIELD M, et al: Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1. Oncogene 13:1789-1799, 1996
91. MIETTINEN HM, EDWARDS SN, JALKANEN M: Analysis of transport and targeting of syndecan-1: Effect of cytoplasmic tail deletions. Mol Biol Cell 5:1325-1339, 1994
92. KIM CW, GOLDBERGER OA, GALLO RL, et al: Members of the syndecan family of heparan sulfate proteoglycans are expressed in distinct cell-, tissue-, and development-specific patterns. Mol Biol Cell 5:797-805, 1994
93. WOODS A, COUCHMAN JR: Syndecan 4 heparan sulfate proteoglycan is a selectively enriched and widespread focal adhesion component. Mol Biol Cell 5:183-192, 1994
94. LONGLEY RL, WOODS A, FLEETWOOD A, et al: Control of morphology, cytoskeleton and migration by syndecan-4. J Cell Sci 112:3421-3431, 1999
95. KARUMANCHI SA, JHA V, RAMCHANDRAN R, et al: Cell surface glypicans are low-affinity endostatin receptors. Mol Cell 7:811-822, 2001
96. SAUNDERS S, PAINE-SAUNDERS S, LANDER AD: Expression of the cell surface proteoglycan glypican-5 is developmentally regulated in kidney, limb, and brain. Dev Biol 190:78-93, 1997
97. GRISARU S, CANO-GAUCI D, TEE J, et al: Glypican-3 modulates BMP-and FGF-mediated effects during renal branching morphogenesis. Dev Biol 231:31-46, 2001
98. WATANABE K, YAMADA H, YAMAGUCHI Y: K-glypican: a novel GPI-anchored heparan sulfate proteoglycan that is highly expressed in developing brain and kidney. J Cell Biol 130:1207-1218, 1995
99. GENGRINOVITCH S, BERMAN B, DAVID G, et al: Glypican-1 is a VEGF165 binding proteoglycan that acts as an extracellular chaperone for VEGF165. J Biol Chem 274:10816-10822, 1999
100. GRISARU S, ROSENBLUM ND: Glypicans and the biology of renal malformations. Pediatr Nephrol 16:302-306, 2001
101. ANDRES JL, STANLEY K, CHEIFETZ S, et al: Membrane-anchored and soluble forms of betaglycan, a polymorphic proteoglycan that binds transforming growth factor-beta. J Cell Biol 109:3137-3145, 1989
102. CHEIFETZ S, MASSAGUE J: Transforming growth factor-beta (TGF-beta) receptor proteoglycan. Cell surface expression and ligand binding in the absence of glycosaminoglycan chains. J Biol Chem 264:12025-12028, 1989
103. SCHAEFER L, MACAKOVA K, RASUK I, et al: Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction. Am J Pathol 160:1181-1191, 2002
104. JALKANEN S, BARGATZE RF, DE LOS TOYOS J, et al: Lymphocyte recognition of high endothelium: Antibodies to distinct epitopes of an 85-95-kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells. J Cell Biol 105:983-990, 1987
105. YU Q, TOOLE BP: A new alternatively spliced exon between v9 and v10 provides a molecular basis for synthesis of soluble CD44. J Biol Chem 271:20603-20607, 1996
106. KATOH S, MCCARTHY JB, KINCADE PW: Characterization of soluble CD44 in the circulation of mice. Levels are affected by immune activity and tumor growth. J Immunol 153:3440-3449, 1994
107. PICKER LJ, DE LOS TOYOS J, TELEN MJ, et al: Monoclonal antibodies against the CD44 [In(Lu)-related p80], and Pgp-1 antigens in man recognize the Hermes class of lymphocyte homing receptors. J Immunol 142:2046-2051, 1989
108. DEED R, ROONEY P, KUMAR P, et al: Early-response gene signalling is induced by angiogenic oligosaccharides of hyaluronan in endothelial cells. Inhibition by non-angiogenic, high-molecular-weight hyaluronan. Int J Cancer 71:251-256, 1997
109. MCKEE CM, PENNO MB, COWMAN M, et al: Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. J Clin Invest 98:2403-2413, 1996
110. LAURENT TC, FRASER JR: Hyaluronan. Faseb J 6:2397-2404, 1992
111. MOHAMADZADEH M, DEGRENDELE H, ARIZPE H, et al: Proinflammatory stimuli regulate endothelial hyaluronan expression and CD44/HA-dependent primary adhesion. J Clin Invest 101:97-108, 1998
112. JONES M, TUSSEY L, ATHANASOU N, et al: Heparan sulfate proteoglycan isoforms of the CD44 hyaluronan receptor induced in human inflammatory macrophages can function as paracrine regulators of fibroblast growth factor action. J Biol Chem 275:7964-7974, 2000
113. CLASPER S, VEKEMANS S, FIORE M, et al: Inducible expression of the cell surface heparan sulfate proteoglycan syndecan-2 (fibroglycan) on human activated macrophages can regulate fibroblast growth factor action. J Biol Chem 274:24113-24123, 1999
114. YAMASHITA Y, ORITANI K, MIYOSHI EK, et al: Syndecan-4 is expressed by B lineage lymphocytes and can transmit a signal for formation of dendritic processes. J Immunol 162:5940-5948, 1999
115. YEAMAN C, RAPRAEGER AC: Membrane-anchored proteoglycans of mouse macrophages: P388D1 cells express a syndecan-4-like heparan sulfate proteoglycan and a distinct chondroitin sulfate form. J Cell Physiol 157:413-425, 1993
116. KANEIDER NC, EGGER P, DUNZENDORFER S, et al: Syndecan-4 as antithrombin receptor of human neutrophils. Biochem Biophys Res Commun 287:42-46, 2001
117. KANEIDER NC, REINISCH CM, DUNZENDORFER S, et al: Syndecan-4 mediates antithrombin-induced chemotaxis of human peripheral blood lymphocytes and monocytes. J Cell Sci 115:227-236, 2002
118. BAGGIOLINI M: Chemokines and leukocyte traffic. Nature 392:565-568, 1998
119. BAZAN JF, BACON KB, HARDIMAN G, et al: A new class of membrane-bound chemokine with a CX3C motif. Nature 385:640-644, 1997
120. KELNER GS, KENNEDY J, BACON KB, et al: Lymphotactin: a cytokine that represents a new class of chemokine. Science 266:1395-1399, 1994
121. HUBER TB, REINHARDT HC, EXNER M, et al: Expression of functional CCR and CXCR chemokine receptors in podocytes. J Immunol 168:6244-6252, 2002
122. PROUDFOOT AE, HANDEL TM, JOHNSON Z, et al: Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA 100:1885-1890, 2003
123. KUSCHERT GS, COULIN F, POWER CA, et al: Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry 38:12959-12968, 1999
124. NETELENBOS T, VAN DEN BORN J, KESSLER FL, et al: Proteoglycans on bone marrow endothelial cells bind and present SDF-1 towards hematopoietic progenitor cells. Leukemia 17:175-184, 2003
125. NOLASCO FE, CAMERON JS, HARTLEY B, et al: Intraglomerular T cells and monocytes in nephritis: Study with monoclonal antibodies. Kidney Int 31:1160-1166, 1987
126. SEGERER S, NELSON PJ, SCHLONDORFF D: Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 11:152-176, 2000
127. SCHLONDORFF D, NELSON PJ, LUCKOW B, et al: Chemokines and renal disease. Kidney Int 51:610-621, 1997
128. WOLF G, ABERLE S, THAISS F, et al: TNF alpha induces expression of the chemoattractant cytokine RANTES in cultured mouse mesangial cells. Kidney Int 44:795-804, 1993
129. ZOJA C, WANG JM, BETTONI S, et al: Interleukin-1 beta and tumor necrosis factor-alpha induce gene expression and production of leukocyte chemotactic factors, colony-stimulating factors, and interleukin-6 in human mesangial cells. Am J Pathol 138:991-1003, 1991
130. WU X, DOLECKI GJ, LEFKOWITH JB: GRO chemokines: A transduction, integration, and amplification mechanism in acute renal inflammation. Am J Physiol 269:F248-F256, 1995
131. BROWN Z, STRIETER RM, CHENSUE SW, et al: Cytokine-activated human mesangial cells generate the neutrophil chemoattractant, interleukin 8. Kidney Int 40:86-90, 1991
132. KAKIZAKI Y, WAGA S, SUGIMOTO K, et al: Production of monocyte chemoattractant protein-1 by bovine glomerular endothelial cells. Kidney Int 48:1866-1874, 1995
133. WOLF G, ZIYADEH FN, THAISS F, et al: Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor. J Clin Invest 100:1047-1058, 1997
134. ITO Y, KAWACHI H, MORIOKA Y, et al: Fractalkine expression and the recruitment of CX3CR1+ cells in the prolonged mesangial proliferative glomerulonephritis. Kidney Int 61:2044-2057, 2002
135. ZERNECKE A, WEBER KS, ERWIG LP, et al: Combinatorial model of chemokine involvement in glomerular monocyte recruitment: role of CXC chemokine receptor 2 in infiltration during nephrotoxic nephritis. J Immunol 166:5755-5762, 2001
136. WEBER KS, VON HUNDELSHAUSEN P, CLARK-LEWIS I, et al: Differential immobilization and hierarchical involvement of chemokines in monocyte arrest and transmigration on inflamed endothelium in shear flow. Eur J Immunol 29:700-712, 1999
137. KAWASHIMA H, WATANABE N, HIROSE M, et al: Collagen XVIII, a basement membrane heparan sulfate proteoglycan, interacts with L-selectin and monocyte chemoattractant protein-1. J Biol Chem 278:13069-13076, 2003
138. LUO J, KATO M, WANG H, et al: Heparan sulfate and chondroitin sulfate proteoglycans inhibit E-selectin binding to endothelial cells. J Cell Biochem 80:522-531, 2001
139. WANG L, BROWN JR, VARKI A, et al: Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L-and P-selectins. J Clin Invest 110:127-136, 2002
140. GOTTE M, JOUSSEN AM, KLEIN C, et al: Role of syndecan-1 in leukocyte-endothelial interactions in the ocular vasculature. Invest Ophthalmol Vis Sci 43:1135-1141, 2002
141. TAMATANI T, KUIDA K, WATANABE T, et al: Molecular mechanisms underlying lymphocyte recirculation. III. Characterization of the LECAM-1 (L-selectin)-dependent adhesion pathway in rats. J Immunol 150:1735-1745, 1993
142. WATANABE N, KAWASHIMA H, LI YF, et al: Identification and characterization of ligands for L-selectin in the kidney. III. Characterization of L-selectin reactive heparan sulfate proteoglycans. J Biochem (Tokyo) 125:826-831, 1999
143. HYNES RO: Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 69:11-25, 1992
144. WRENSHALL LE, STEVENS RB, CERRA FB, et al: Modulation of macrophage and B cell function by glycosaminoglycans. J Leukoc Biol 66:391-400, 1999
145. WUTHRICH RP: The proinflammatory role of hyaluronan-CD44 interactions in renal injury. Nephrol Dial Transplant 14:2554-2556, 1999
146. JUN Z, HILL PA, LAN HY, et al: CD44 and hyaluronan expression in the development of experimental crescentic glomerulonephritis. Clin Exp Immunol 108:69-77, 1997
147. OERTLI B, BECK-SCHIMMER B, FAN X, et al: Mechanisms of hyaluronan-induced up-regulation of ICAM-1 and VCAM-1 expression by murine kidney tubular epithelial cells: hyaluronan triggers cell adhesion molecule expression through a mechanism involving activation of nuclear factor-kappa B and activating protein-1. J Immunol 161:3431-3437, 1998
148. KEY NS, PLATT JL, VERCELLOTTI GM: Vascular endothelial cell proteoglycans are susceptible to cleavage by neutrophils. Arterioscler Thromb 12:836-842, 1992
149. LIDER O, CAHALON L, GILAT D, et al: A disaccharide that inhibits tumor necrosis factor alpha is formed from the extracellular matrix by the enzyme heparanase. Proc Natl Acad Sci USA 92:5037-5041, 1995
150. HEERINGA P, VAN DEN BORN J, BROUWER E, et al: Elastase, but not proteinase 3 (PR3), induces proteinuria associated with loss of glomerular basement membrane heparan sulphate after in vivo renal perfusion in rats. Clin Exp Immunol 105:321-329, 1996
151. OKADA Y, YAMADA S, TOYOSHIMA M, et al: Structural recognition by recombinant human heparanase that plays critical roles in tumor metastasis. Hierarchical sulfate groups with different effects and the essential target disulfated trisaccharide sequence. J Biol Chem 277:42488-42495, 2002
152. BARTLETT MR, UNDERWOOD PA, PARISH CR: Comparative analysis of the ability of leucocytes, endothelial cells and platelets to degrade the subendothelial basement membrane: Evidence for cytokine dependence and detection of a novel sulfatase. Immunol Cell Biol 73:113-124, 1995
153. OLOFSSON AM, VESTBERG M, HERWALD H, et al: Heparin-binding protein targeted to mitochondrial compartments protects endothelial cells from apoptosis. J Clin Invest 104:885-894, 1999
154. GAUTAM N, OLOFSSON AM, HERWALD H, et al: Heparin-binding protein (HBP/CAP37): A missing link in neutrophil-evoked alteration of vascular permeability. Nat Med 7:1123-1127, 2001
155. NATH KA, FISCHEREDER M, HOSTETTER TH: The role of oxidants in progressive renal injury. Kidney Int 45 (Suppl 45):S111-S115, 1994
156. JOHNSON RJ, LOVETT D, LEHRER RI, et al: Role of oxidants and proteases in glomerular injury. Kidney Int 45:352-359, 1994
157. KASHIHARA N, WATANABE Y, MAKINO H, et al: Selective decreased de novo synthesis of glomerular proteoglycans under the influence of reactive oxygen species. Proc Natl Acad Sci USA 89:6309-6313, 1992
158. MOSELEY R, WADDINGTON R, EVANS P, et al: The chemical modification of glycosaminoglycan structure by oxygen-derived species in vitro. Biochim Biophys Acta 1244:245-252, 1995
159. PANASYUK A, FRATI E, RIBAULT D, et al: Effect of reactive oxygen species on the biosynthesis and structure of newly synthesized proteoglycans. Free Radic Biol Med 16:157-167, 1994
160. VAN BRUGGEN MC, KRAMERS K, HYLKEMA MN, et al: Decrease of heparan sulfate staining in the glomerular basement membrane in murine lupus nephritis. Am J Pathol 146:753-763, 1995
161. SORENSSON J, BJORNSON A, OHLSON M, et al: Synthesis of sulfated proteoglycans by bovine glomerular endothelial cells in culture. Am J Physiol Renal Physiol 284:F373-F380, 2003
162. HILL PA, LAN HY, NIKOLIC-PATERSON DJ, et al: The ICAM-1/LFA-1 interaction in glomerular leukocytic accumulation in anti-GBM glomerulonephritis. Kidney Int 45:700-708, 1994
163. TANG WW, QI M, WARREN JS: Monocyte chemoattractant protein 1 mediates glomerular macrophage infiltration in anti-GBM Ab GN. Kidney Int 50:665-671, 1996
164. KASHIHARA N, WATANABE Y, MAKINO H, et al: Interleukin-1-induced alterations in glomerular proteoglycans: Biochemical and tissue autoradiographic aspects. J Am Soc Nephrol 3:203-213, 1992
165. GALLO R, KIM C, KOKENYESI R, et al: Syndecans-1 and -4 are induced during wound repair of neonatal but not fetal skin. J Invest Dermatol 107:676-683, 1996
166. ZHANG Y, PASPARAKIS M, KOLLIAS G, et al: Myocyte-dependent regulation of endothelial cell syndecan-4 expression. Role of TNF-alpha. J Biol Chem 274:14786-14790, 1999
167. DENNISSEN MA, JENNISKENS GJ, PIEFFERS M, et al: Large, tissue-regulated domain diversity of heparan sulfates demonstrated by phage display antibodies. J Biol Chem 277:10982-10986, 2002
168. BINGLEY JA, HAYWARD IP, GIRJES AA, et al: Expression of heparan sulphate N-deacetylase/N-sulphotransferase by vascular smooth muscle cells. Histochem J 34:131-137, 2002
169. FORSBERG E, KJELLEN L: Heparan sulfate: Lessons from knockout mice. J Clin Invest 108:175-180, 2001
170. MERRY CL, BULLOCK SL, SWAN DC, et al: The molecular phenotype of heparan sulfate in the Hs2st-/-mutant mouse. J Biol Chem 276:35429-35434, 2001
171. MERRY CL, WILSON VA: Role of heparan sulfate-2-O-sulfotransferase in the mouse. Biochim Biophys Acta 1573:319-327, 2002
172. LI JP, GONG F, HAGNER-MCWHIRTER A, et al: Targeted disruption of a murine glucuronyl C5-epimerase gene results in heparan sulfate lacking L-iduronic acid and in neonatal lethality. J Biol Chem 278:28363-28366, 2003
173. IMIELA J, NOSARZEWSKI J, GORSKI A: Oral heparin in the treatment of rheumatoid arthritis. Arch Immunol Ther Exp (Warsz) 43:313-315, 1995
174. CHEN HC, GUH JY, SHIN SJ, et al: Insulin and heparin suppress superoxide production in diabetic rat glomeruli stimulated with low-density lipoprotein. Kidney Int 59 (Suppl 78:S124-S127, 2001
175. WEIGERT C, BRODBECK K, HARING HU, et al: Low-molecular-weight heparin prevents high glucose-and phorbol ester-induced TGF-beta 1 gene activation. Kidney Int 60:935-943, 2001
176. ROGERS C, WELT FG, KARNOVSKY MJ, et al: Monocyte recruitment and neointimal hyperplasia in rabbits. Coupled inhibitory effects of heparin. Arterioscler Thromb Vasc Biol 16:1312-1318, 1996
177. FRYER A, HUANG YC, RAO G, et al: Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung. J Pharmacol Exp Ther 282:208-219, 1997
178. NETELENBOS T, VAN DEN BORN J, KESSLER FL, et al: In vitro model for hematopoietic progenitor cell homing reveals endothelial heparan sulfate proteoglycans as direct adhesive ligands. J Leukoc Biol 74:1035-1044, 2003
179. NETELENBOS T, ZUIJDERDUIJN S, VAN DEN BORN J, et al: Proteoglycans guide SDF-1-induced migration of hematopoietic progenitor cells. J Leukoc Biol 72:353-362, 2002
180. MATSUDA M, SHIKATA K, SHIMIZU F, et al: Therapeutic effect of sulphated hyaluronic acid, a potential selectin-blocking agent, on experimental progressive mesangial proliferative glomerulonephritis. J Pathol 198:407-414, 2002